XML 56 R16.htm IDEA: XBRL DOCUMENT

Revenue Recognition

9 Months Ended

Sep. 30, 2019

9. Revenue Recognition

All of our product revenue consisted of sales of HEPLISAV-B in the U.S. For the nine months ended September 30, 2019 and 2018, our three largest Customers collectively represented approximately 63% and 68% of our product revenue, respectively. The following table summarizes balances and activity in each of the product revenue allowance and reserve categories for the nine months ended September 30, 2019 (in thousands):

	Chargebacks, distribution fees, discounts and other fees			Returns			Total
Balance at December 31, 2018	$	1,736		$	569		$	2,305
Provision related to current period sales		10,937			1,724			12,661
Credit or payments made during the period		(8,689	)		(408	)		(9,097	)
Balance at September 30, 2019	$	3,984		$	1,885		$	5,869

Reserves for chargebacks and discounts totaling $2.7 million were recorded as reductions of accounts receivable at September 30, 2019. The remaining reserves balances totaling $3.2 million were recorded as accrued liabilities at September 30, 2019.